Literature DB >> 15721178

Profiling at recombinant homomeric and heteromeric rat P2X receptors identifies the suramin analogue NF449 as a highly potent P2X1 receptor antagonist.

Jürgen Rettinger1, Kirsten Braun, Henrike Hochmann, Matthias U Kassack, Heiko Ullmann, Peter Nickel, Günther Schmalzing, Günter Lambrecht.   

Abstract

P2X receptors are cation channels gated by extracellular ATP and related nucleotides. Because of the widespread distribution of P2X receptors and the high subtype diversity, potent and selective antagonists are needed to dissect their roles in intact tissues. Based on suramin as a lead compound, several derivates have been described that block recombinant P2X receptors with orders of magnitude higher potency than suramin. Here we characterized the suramin analogue 4,4',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis(carbonylimino)))tetrakis-benzene-1,3-disulfonic acid (NF449) with respect to its potency to antagonize ATP or alphabeta-methyleneadenosine 5'-trisphosphate-induced inward currents of homomeric rat P2X(1)-P2X(4) receptors or heteromeric P2X(1 + 5) and P2X(2+3) receptors, respectively. NF449 most potently blocked P2X(1) and P2X(1 + 5) receptors with IC(50) values of 0.3 nM and 0.7 nM, respectively. Three to four orders of magnitude higher NF449 concentrations were required to block homomeric P2X(3) or heteromeric P2X(2 + 3) receptors (IC(50) 1.8 and 0.3 microM, respectively). NF449 was least potent at homomeric P2X(2) receptors (IC(50) 47 microM) and homomeric P2X(4) receptors (IC(50) > 300 microM). Altogether, these results characterize NF449 as the so far most potent and selective antagonist of receptors incorporating the P2X(1) subunit such as the P2X(1) homomer and the P2X(1 + 5) heteromer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15721178     DOI: 10.1016/j.neuropharm.2004.11.003

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  30 in total

1.  Development of a comprehensive set of P2 receptor pharmacological research compounds.

Authors:  R A Felix; S Martin; S Pinion; D J Crawford
Journal:  Purinergic Signal       Date:  2011-11-04       Impact factor: 3.765

Review 2.  Molecular and functional properties of P2X receptors--recent progress and persisting challenges.

Authors:  Karina Kaczmarek-Hájek; Eva Lörinczi; Ralf Hausmann; Annette Nicke
Journal:  Purinergic Signal       Date:  2012-05-01       Impact factor: 3.765

3.  Cell-autonomous regulation of hematopoietic stem cell cycling activity by ATP.

Authors:  A Casati; M Frascoli; E Traggiai; M Proietti; U Schenk; F Grassi
Journal:  Cell Death Differ       Date:  2010-08-27       Impact factor: 15.828

4.  The novel suramin analogue NF864 selectively blocks P2X1 receptors in human platelets with potency in the low nanomolar range.

Authors:  Susanne Horner; Kirsten Menke; Caren Hildebrandt; Matthias U Kassack; Peter Nickel; Heiko Ullmann; Martyn P Mahaut-Smith; Günter Lambrecht
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-09-13       Impact factor: 3.000

Review 5.  Pharmacology of P2X channels.

Authors:  Joel R Gever; Debra A Cockayne; Michael P Dillon; Geoffrey Burnstock; Anthony P D W Ford
Journal:  Pflugers Arch       Date:  2006-04-29       Impact factor: 3.657

Review 6.  Activation and regulation of purinergic P2X receptor channels.

Authors:  Claudio Coddou; Zonghe Yan; Tomas Obsil; J Pablo Huidobro-Toro; Stanko S Stojilkovic
Journal:  Pharmacol Rev       Date:  2011-07-07       Impact factor: 25.468

7.  High-Throughput HIV-Cell Fusion Assay for Discovery of Virus Entry Inhibitors.

Authors:  Mariana Marin; Yuhong Du; Charline Giroud; Jeong Hwa Kim; Min Qui; Haian Fu; Gregory B Melikyan
Journal:  Assay Drug Dev Technol       Date:  2015-04-14       Impact factor: 1.738

Review 8.  P2X receptors as drug targets.

Authors:  R Alan North; Michael F Jarvis
Journal:  Mol Pharmacol       Date:  2012-12-19       Impact factor: 4.436

Review 9.  Agonists and antagonists for P2 receptors.

Authors:  Kenneth A Jacobson; Stefano Costanzi; Bhalchandra V Joshi; Pedro Besada; Dae Hong Shin; Hyojin Ko; Andrei A Ivanov; Liaman Mamedova
Journal:  Novartis Found Symp       Date:  2006

10.  Purinoreceptor-mediated current in myocytes from renal resistance arteries.

Authors:  Maksym I Harhun; Oleksandr V Povstyan; Dmitri V Gordienko
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.